{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:28:57Z","timestamp":1782955737273,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.vaccine.2023.07.054","type":"journal-article","created":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T06:54:08Z","timestamp":1690700048000},"page":"5603-5613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Variability of in vivo potency assays of whole-cell pertussis, inactivated polio, and meningococcal B vaccines"],"prefix":"10.1016","volume":"41","author":[{"given":"Cerissa","family":"van Walstijn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7566-1776","authenticated-orcid":false,"given":"Stefan","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Care","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8954-9475","authenticated-orcid":false,"given":"Peter","family":"Rigsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4798-9911","authenticated-orcid":false,"given":"Eli-Boaz","family":"Clapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Markey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-952X","authenticated-orcid":false,"given":"Rob J.","family":"Vandebriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Stickings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9206-4236","authenticated-orcid":false,"given":"Marcel H.N.","family":"Hoefnagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2023.07.054_b0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2023.07.054_b0010","doi-asserted-by":"crossref","first-page":"D7","DOI":"10.1016\/j.vaccine.2011.06.080","article-title":"The eradication of smallpox\u2013an overview of the past, present, and future","volume":"29","author":"Henderson","year":"2011","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2023.07.054_b0015","doi-asserted-by":"crossref","first-page":"470","DOI":"10.15585\/mmwr.mm6518a4","article-title":"Progress toward polio eradication\u2014worldwide, 2015\u20132016","volume":"65","author":"Morales","year":"2016","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.07.054_b0020","unstructured":"Commission, E., EudraLex Annex 16: Certification by a Qualified Person and Batch Release. Brussels; 2015."},{"key":"10.1016\/j.vaccine.2023.07.054_b0025","unstructured":"European Pharmacopoeia. Batch Release for Human Biologicals: vaccines, blood and plasma derivatives; 2022 [cited 2022 24 November 2022]; Available from: https:\/\/www.edqm.eu\/en\/batch-release-for-human-biologicals-vaccines-blood-and-plasma-derivatives."},{"key":"10.1016\/j.vaccine.2023.07.054_b0030","unstructured":"World Health Organization, Manual for Quality Control of Diphtheria, Tetanus and Pertussis Vaccines, in Immunization, Vaccines and Biologicals. World Health Organization: Geneva; 2013."},{"issue":"3","key":"10.1016\/j.vaccine.2023.07.054_b0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/14760584.8.3.313","article-title":"Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement","volume":"8","author":"Hendriksen","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2023.07.054_b0040","unstructured":"World Health Organization, Recommendations to assure the quality, safety and efficacy of typhoid conjugate vaccines, Annex 2, TRS No 1030; 2020. p. 79-158."},{"key":"10.1016\/j.vaccine.2023.07.054_b0045","unstructured":"World Health Organization, Recommendations for the production and control of Meningococcal group C conjugate vaccines, Annex 2, TRS No 924; 2004. p. 102-128."},{"key":"10.1016\/j.vaccine.2023.07.054_b0050","unstructured":"EDQM, Text 01160 (01\/2019) Typhoid Polysaccharide Vaccine, in European Pharmacopoeia 11.1., European Directorate for the Quality of Medicines & HealthCare Strasbourg; 2023, p. 1108-1110."},{"key":"10.1016\/j.vaccine.2023.07.054_b0055","unstructured":"EDQM, Text 03066 (07\/2019) Meningococcal Group A, C, W135 and Y conjugate vaccine, in European Pharmacopoeia 11.1., European Directorate for the Quality of Medicines & HealthCare Strasbourg; 2023, p. 1073-1075."},{"key":"10.1016\/j.vaccine.2023.07.054_b0060","unstructured":"EDQM, Text 02150 (01\/2019) Pneumococcal polysaccharide conjugate vaccine adsorbed, in European Pharmacopoeia 11.1., European Directorate for the Quality of Medicines & HealthCare Strasbourg; 2023, p. 1084-1086."},{"key":"10.1016\/j.vaccine.2023.07.054_b0065","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/5584_2016_21","article-title":"Pertussis: history of the disease and current prevention failure","author":"Kuchar","year":"2016","journal-title":"Pulmonary Dysfunction Disease"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.054_b0070","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biologicals.2010.12.001","article-title":"The consistency approach for quality control of vaccines\u2013a strategy to improve quality control and implement 3Rs","volume":"39","author":"De Mattia","year":"2011","journal-title":"Biologicals"},{"issue":"3","key":"10.1016\/j.vaccine.2023.07.054_b0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4155\/bio-2017-0176","article-title":"Principles of vaccine potency assays","volume":"10","author":"Verch","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.vaccine.2023.07.054_b0080","unstructured":"EDQM, Text 50214 (01\/2020). Substitution of in vivo method(s) by in vitro method(s) for the quality control of vaccines, in European Pharmacopoeia 11.1., European Directorate for the Quality of Medicines & HealthCare Strasbourg; 2023."},{"issue":"12","key":"10.1016\/j.vaccine.2023.07.054_b0085","first-page":"65","article-title":"EDQM\u2019s 3R activities in the field of quality control of vaccines","volume":"1","author":"Milne","year":"2012","journal-title":"ALTEX Proc"},{"key":"10.1016\/j.vaccine.2023.07.054_b0090","series-title":"The principles of humane experimental technique","author":"Russell","year":"1959"},{"issue":"18","key":"10.1016\/j.vaccine.2023.07.054_b0095","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.vaccine.2021.03.078","article-title":"Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines","volume":"39","author":"Stalpers","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.054_b0100","unstructured":"World Health Organization, Recommendations to assure the quality, safety and efficacy of tetanus vaccines (adsorbed), Annex 5, TRS No 980; 2014."},{"key":"10.1016\/j.vaccine.2023.07.054_b0105","unstructured":"World Health Organization, Recommendations to assure the quality, safety and efficacy of diphtheria vaccines (adsorbed), Annex 4, TRS No 980; 2014."},{"key":"10.1016\/j.vaccine.2023.07.054_b0110","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.biologicals.2017.02.002","article-title":"G-protein based ELISA as a potency test for rabies vaccines","volume":"46","author":"Chabaud-Riou","year":"2017","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2023.07.054_b0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.biologicals.2019.05.004","article-title":"Potency test to discriminate between differentially over-inactivated rabies vaccines: Agreement between the NIH assay and a G-protein based ELISA","volume":"60","author":"Toinon","year":"2019","journal-title":"Biologicals"},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.054_b0120","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/biol.1993.1070","article-title":"Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains","volume":"21","author":"Sawyer","year":"1993","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2023.07.054_b0125","unstructured":"EDQM, Text 00451 (04\/2023) Rabies vaccine (inactivated) for veterinary use, in European Pharmacopoeia 11.1., European Directorate for the Quality of Medicines & HealthCare Strasbourg; 2022, p. 4609-4612."},{"key":"10.1016\/j.vaccine.2023.07.054_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biologicals.2022.11.002","article-title":"Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers","volume":"81","author":"Lilley","year":"2023","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2023.07.054_b0135","unstructured":"EDQM, Text 20720 (04\/2022) In vivo assay of poliomyelitis vaccine (inactivated), in European Pharmacopoeia 11.1., European Directorate for the Quality of Medicines & HealthCare Strasbourg; 2023."},{"key":"10.1016\/j.vaccine.2023.07.054_b0140","article-title":"Development of a multiplex-based immunoassay for the characterization of diphtheria, tetanus and acellular pertussis antigens in human combined DTaP vaccines","author":"Maxime","year":"2023","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.054_b0145","first-page":"1","article-title":"Validation study to evaluate the reproducibility of a candidate in vitro potency assay of Newcastle disease vaccines and to establish the suitability of a candidate biological reference preparation","volume":"2004","author":"Claassen","year":"2004","journal-title":"Pharmeuropa Bio"},{"key":"10.1016\/j.vaccine.2023.07.054_b0150","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.provac.2011.10.020","article-title":"Animal refinement and reduction: alternative approaches for potency testing of diphtheria and tetanus vaccines","volume":"5","author":"Stickings","year":"2011","journal-title":"Proc Vaccinol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.054_b0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nri.2016.125","article-title":"Human immune system variation","volume":"17","author":"Brodin","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2023.07.054_b0160","first-page":"1","article-title":"Genetically defined strains in drug development and toxicity testing. Mouse Models for Drug Discovery","author":"Festing","year":"2016","journal-title":"Methods and Protocols"},{"issue":"5","key":"10.1016\/j.vaccine.2023.07.054_b0165","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/0192623310373776","article-title":"Inbred strains should replace outbred stocks in toxicology, safety testing, and drug development","volume":"38","author":"Festing","year":"2010","journal-title":"Toxicol Pathol"},{"issue":"12","key":"10.1016\/j.vaccine.2023.07.054_b0170","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41592-018-0224-7","article-title":"Comparing phenotypic variation between inbred and outbred mice","volume":"15","author":"Tuttle","year":"2018","journal-title":"Nat Methods"},{"issue":"3","key":"10.1016\/j.vaccine.2023.07.054_b0175","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/ilar\/ilu036","article-title":"Evidence should trump intuition by preferring inbred strains to outbred stocks in preclinical research","volume":"55","author":"Festing","year":"2014","journal-title":"ILAR J"},{"issue":"3","key":"10.1016\/j.vaccine.2023.07.054_b0180","first-page":"466","article-title":"Genome-wide association mapping of the antibody response to Diphtheria, Tetanus and acellular Pertussis vaccine in mice","volume":"215","author":"Mosley","year":"2017","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2023.07.054_b0185","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000106559","article-title":"Genetic variation in the response to vaccination","volume":"10","author":"Kimman","year":"2007","journal-title":"Public Health Genomics"},{"key":"10.1016\/j.vaccine.2023.07.054_b0190","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/0264-410X(91)90180-E","article-title":"Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type b polysaccharide\u2014Neisseria meningitidis outer membrane protein","volume":"9","author":"Ahonkhai","year":"1991","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.054_b0195","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1128\/CVI.00561-13","article-title":"Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens","volume":"21","author":"Nagaputra","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2023.07.054_b0200","unstructured":"CHMP, Trumenba: EPAR - European assessment report: 2.2.4. Discussion on chemical, pharmaceutical and biological aspects. C.f.M.P.f.H. Use, editor. European Medicines Agency: London; 2017, p. 19\/139."},{"key":"10.1016\/j.vaccine.2023.07.054_b0205","unstructured":"EDQM, Text 00214 corrected 10.0. Poliomyelitis vaccine (inactivated) , in European Pharmacopoeia 11.1. European Directorate for the Quality of Medicines & HealthCare Strasbourg; 2023, p. 1087-1090."},{"key":"10.1016\/j.vaccine.2023.07.054_b0210","unstructured":"EDQM, Text 20715 Assay of hepatitis B vaccine (rDNA), in European Pharmacopoeia 11.1., European Directorate for the Quality of Medicines & HealthCare Strasbourg; 2023, p. 300-301."},{"key":"10.1016\/j.vaccine.2023.07.054_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2020.112939","article-title":"Development of competitive inhibition ELISA as an effective potency test to analyze human rabies vaccines and assessment of the antigenic epitope of rabies glycoprotein","volume":"492","author":"Soni","year":"2021","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.054_b0220","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/14760584.2023.2198601","article-title":"Rational arguments for regulatory acceptance of consistency testing: benefits of non-animal testing over in vivo release testing of vaccines","volume":"22","author":"Hoefnagel","year":"2023","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.054_b0225","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/14760584.2023.2178421","article-title":"Research progress on substitution of in vivo method (s) by in vitro method (s) for human vaccine potency assays","volume":"22","author":"Zhang","year":"2023","journal-title":"Expert Rev Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2300885X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2300885X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:31:14Z","timestamp":1759404674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2300885X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":45,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0264410X2300885X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.054","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variability of in vivo potency assays of whole-cell pertussis, inactivated polio, and meningococcal B vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}